The primary finding was that fenofibrate (160 mg/day) was well tolerated but did not influence beta cell function in adults and adolescents with newly diagnosed type 1 diabetes, as indicated by unchanged C-peptide secretion, insulin usage and glycaemic control. Here, INS is linked to type 1 diabetes mellitus.